

Supplementary Table 1. Chemotherapy after EUS-HGS

	Chemotherapy (n=26)	No chemotherapy (n=36)	p-value*
Age at stent placement (yr)	64 (38–83)	69 (43–92)	
Male	13 (50.0)	19 (52.8)	
Performance status, 0/1/2	17/9/0	16/14/6	0.059
Long uncovered portion (20 mm)	17 (65.4)	13 (36.1)	0.023
Recurrent biliary obstruction	14 (53.8)	7 (19.4)	0.005
Total bilirubin before EUS-HGS	1.2 (0.3–7.1)	1.8 (0.5–16)	0.065
Chemotherapy before EUS-HGS	14 (53.8)	27 (75.0)	0.082
Cholangitis before EUS-HGS	14 (53.8)	23 (63.9)	
Clinical success	26 (100.0)	27 (75.0)	0.008
Procedure time (min)	24 (11–113)	18 (7–46)	0.030
Length of hospital stay after EUS-HGS (day)	8 (4–32)	11 (1–59)	0.015
Adverse events	4 (15.4)	7 (19.4)	
Progression-free survival (mo)	3.4 (0.5–27.8)		
Overall survival (mo)	6.1 (0.5–29)	2.7 (0–15.7)	<0.001

Values are presented as number (%) or median (range).

EUS-HGS, endoscopic ultrasound-guided hepaticogastrostomy.

* $p < 0.1$.